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S U M M A R Y
Cytogenetic analysis and loss of heterozygosity studies have shown that deletions of the
short arm of chromosome 3, in particular of the distal part of band p21, are a common
abnormality in lung tumours.
Chapter 1 of this thesis gives a review of the literature on the deletions. They have
been found in virtually 100 7o of small cell lung cancer (SCLC) tumours and in 38 7o to IO0
7o of the non-SCLC carcinomas analysed in the literature. Also in other cancer types,
including carcinoma of the breast, uterus, ovary, testis, kidney, squamous cell carcinoma of
head and neck and gastrointestinal tumours, deletion of the 3p21.3 region have been
described. This suggests the presence of (a) broad spectrum tumour suppressor gene(s) in
this region involved in the development of these various lumour types. In several SCLC
cell lines overlapping homozygous deletions have been found, including a relatively small
one (440 kb) in cell line GLC20 which has been described in previous work of the
Department. Homozygous deletions partly coinciding with the deletion overlap of the cell
lines have also been found in primary lung tumours. The commonly deleted region,
denominated the critical lung cancer region, is 370 kb. In vivo functional assays of tumour
suppressor activity support the assumption that 3p21.3 contains (a) tumour suppressor
gene(s). The tumourigenicity of a lung adenocarcinoma cell line was suppressed by
introducing a complete human chromosome 3 into this cell line. Additionally, chromosome
3 fragments which include the 3p21.3 region were able to suppress the tumourigenicity of
other tumour type cell lines, including a mouse fibrosarcoma cell line. This suggests that
the 3p21 .3 region may contain a cross-species acting tumour suppressor gene.
In chapter 2 the 440 kb homozygous deletion of the SCLC cell line GLCZO was taken
as a starting-point for the search for a tumour suppressor gene in the 3p2L3 critical lung
cancer region. A cosmid contig was constructed for the region which is homozygously
deleted in GLC20. One of the cosmids appeared to be instable and from 40-80 kb of DNA
distal to this cosmid no new cosmids could be isolated. 3' Exon trapping experiments of 14
cosmids of the contig resulted in the isolation of three genes, indicated as 64A, 648 and
15ó4. Sequence similarity analysis showed that gene 648 is homologous to the yeast
.J
nrtrogcn pcrmease rcgulatof NPR2. N<l inclicntion was Íbuncl alkrwing to attl ibutc a possiblc
lumour suppressor lïnction to one o1'the gcnes.
Chaptcr'3 describes the isolzrtion of gcncs RBM5, located in thc rcgion hornozygously
delctcd in GLC20, and RBMó, clossing the tclorneric breakpoint oÍ this clelction. Sequencc
compiirison revcaled that at thc amino acid level both ,uenes show 30% iclcntity. Thcy
contil in two zit.tc Í ingcr rnotiÍ-s, a bipaltitc nuclcar signal ancl two RNA bincling rtroti l.s,
suggcsting that the proteins Íbr which RIIM5 md RBM(t are coding havc a DNA/RNA
binding lunction nnd are located in thc nuclcus. Northcrn, Southcrn ancl SSCP analysis clicl
not rcveal aberrations which could possibly havc an influcnce on the protcin l 'unction. An
alternative splicc variant oÍ'-9enc RBMó in which cxon -5 is ntissin-q was clctcctccl in nor.rnal
lung t issuc as wcl l  as in  lung tumour cel l  l incs.  In  normal  ung t issue,  the rc lat ivc amount  oÍ
thc shortet'transcript was tnuch grcater thiin that in lung tuntour cell l incs. Sincc thc
cxclusion of exon 5 r'csults in a Íiamcshil i which would cause u truncatccl protcin ol ' -520
amino acids instcad of  I123 arn ino ac ids,  the qucst ion is  ra iscc l  whethcr  sonrc tuulour
supprcssor' Í 'unction rnay be attributed to thc derived shorter protcin.
Clraptcr 4 discusses a genomic homology of thc 3p2 1.3 rcgion. RIIMS and, RIIMó
show not  only  s i rn i lar i ty  to  each othcr ,  br- r t  a lso to DXS8237E, a gcne at  Xpl l .3-1] r .23.
DXS8237E maps lcss than 20 kb upstrcam ol' UBEI . A hornologuc o| LIBEI , L/REIL nttrlts
about 265 kb l iom RBM5. DXS8237E tnd UBEI on chrourosomc X hnvc the sarnc
orientation, whet'cas on chrornosclme 3 the olientation ol'RBM5 as well as that oÍ'RBM(t',trc
opposi te to the or ientat ion of  UBEIL.  Prcsurnably,  par t  oÍ ' tho Xpl l .3-1 l t .23 rcgion has
clupl icated to chromosotnc 3 lb l lowed by ac lupl icat ion wi th in th is  region on c l . r lornosonrc 3.
This nriglrt explain the positions oÍ IIBM5 and RBMó. An invsrsion at any slage ol'thc
cvolut ionary devclopment  o l ' the human ,qenome would cxpla in thc change in or icntat ion o l '
thc genes on chrotnosornc 3 as comparccl with that ol 'thc 
-qencs on the X chr'<lrnos<tmc.
Chaptcr'5 presents a l irnctional Lcst fbl tumour supprcssion. A total ol ' l9 gencs lras
bccn isolatccl l iorn thc crit ical lung canccl rcgion to clatc. To none ol'thcsc has a tunlour
supprcssol' Íunction bccn assigncd, with thc exccption, howevcr, oÍ- SEMA 1V. This genc
has reccntly becn shown by others to supprcss the tumourigcnicity of it nrousc fibrosalcorna
ccll l ine in irnmune-dcÍlcient rnice. To invcstigate whether to this gcne fl 'om thc crit ical
lung oancer rcgion can excrt i i  turnour supprcssion function in hurnan lung calcinorna cclls

































tumour supprcssor activity of individual 120 kb PACs in the mouse fibrosarcoma cell l ine
A9 and in a suitablc human lung canccr cell l ine. For this, a contig ol '8 PACs containing irn
eukaryotic selection markcr was constructed which overlapped thc 440 kb lcgion
homozygously deleted in the GLC20 cell l ine. All l9 known gcnes have been mappecl on
this contig. PAC-4 which contains the genes RBMS, SEMA IV, GNAT1,54l7 ancl GNAI2
was assayed fbr its abil ity to suppress the tumourigenicity of A9 and oÍ'the SCLC cell l inc
GLC45 in athymic mice. A9 cloncs transfècted with this PAC indeed ciiuscd significantly
smaller tumours than the parental A9 cell l ine. A tumour suppressing efl 'cct o1'PAC-4 was,
however, not observed in the SLCL cell l ine GLC45. These prelirninary results suggcst hat
the mechanism involved in tumour suppression in the A9 mouse Ílbrosar-comil cells, rlay
not work in human lung carcinorna. If truc, then all individual PACs ol'the r:ontig, or even
all individuitl genes need to bc assayed lbr tumour suppression i lctivity. Thc tools Íor that
are there, as shown in this f innl chapter.
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